Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03868254 · ClinicalTrials.gov registry record
Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)
A clinical trial of Glaucoma, sponsored by Allergan.
- Completed
- Registry status
- 174
- Enrollment target
- 1
- Study location
NCT03868254: Completed study of Glaucoma, sponsored by Allergan.
NCT03868254 is a study of Glaucoma that has completed, run by Allergan. The registered enrollment target is 174 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03868254, a study of Glaucoma, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 174 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with phacoemulsification from 1 January 2014 to 1 October 2015.
Primary Outcome
IOP is a measurement of the fluid pressure inside the eye. A negative change from Baseline indicates an improvement.
Conditions Studied
Interventions
- PROCEDURE Phacoemulsification
- DEVICE XEN Group
Study Locations (1)
California
- Clinical Trials Registry Team - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2019-04-05 |
| Est. Completion | 2019-10-25 |
What the finished NCT03868254 record still lists
NCT03868254 is an observational study that tracks outcomes without assigning an intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Phacoemulsification is the first listed.
NCT03868254 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03868254 about?
NCT03868254 is a clinical study titled "Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)". A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with phacoemulsification from 1 January 2014 to 1 October 2015.
What is the current status of trial NCT03868254?
This trial is currently completed. The enrollment target is 174 participants. The study started on 2019-04-05. Estimated completion is 2019-10-25.
What conditions does trial NCT03868254 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT03868254?
The interventions under investigation include: Phacoemulsification (PROCEDURE), XEN Group (DEVICE).
Who is sponsoring clinical trial NCT03868254?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03868254 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03868254's enrollment target sits among peer trials
174 30th of 92 higher than 63 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Eye Pressure Lowering Surgery
RECRUITING
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI